InvestSMART

Acumentis Group Limited (ASX: ACU) - Announcements

- Current share price for ACU : $0.088

ASX company news and announcements for Acumentis Group Limited (ACU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acumentis Group Limited (ACU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acumentis Group Limited (ACU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Acumentis Group Limited (ACU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$20 Acuvax Affliate Receives Capital Injection 22 Dec 2009 4:32PM $0.016 $0.088 risen by 450%
$20 Acuvax Affiliate Reorganises 14 Dec 2009 10:31AM $0.014 $0.088 risen by 528.57%
$20 Appendix 4C - quarterly 30 Oct 2009 5:25PM $0.020 $0.088 risen by 340%
$20 Acuvax Affiliate Sales Top USD$1M in 2009 8 Oct 2009 5:41PM $0.019 $0.088 risen by 363.16%
$20 RP101 Clinical Trials 6 Oct 2009 1:31PM $0.020 $0.088 risen by 340%
$20 Share Purchase Plan 21 Sep 2009 12:15PM $0.027 $0.088 risen by 225.93%
$20 Placement and Resignation of a Director 17 Sep 2009 3:22PM $0.031 $0.088 risen by 183.87%
$20 Preliminary Final Report 31 Aug 2009 6:13PM n/a $0.088 n/a
$20 First Human Trials for Recombinant Dengue Fever Vaccine 26 Aug 2009 8:37AM $0.048 $0.088 risen by 83.33%
$20 Acuvax Advances Technology Collaboration and Capital Raising 21 Aug 2009 10:32AM $0.031 $0.088 risen by 183.87%
$20 Affiliate Wins Major Grant to Fight Tick Borne Encephalitis 12 Aug 2009 10:37AM $0.040 $0.088 risen by 120%
$20 Commitments Test Entity - Fourth Quarter Report 31 Jul 2009 4:46PM $0.040 $0.088 risen by 120%
$20 Appendix 4C - quarterly 28 Apr 2009 6:45PM $0.048 $0.088 risen by 83.33%
$20 Acuvax Takes Cash Gain on Portion of Oncology Assets 15 Apr 2009 10:26AM $0.030 $0.088 risen by 193.33%
$20 Acuvax Oncology Portfolio Advances in the USA 19 Mar 2009 12:08PM $0.031 $0.088 risen by 183.87%
$20 Half Yearly Report and Accounts 27 Feb 2009 2:55PM $0.031 $0.088 risen by 183.87%
$20 Hawaii Biotech Favorable Interim Results for West Nile Virus 26 Feb 2009 11:03AM $0.022 $0.088 risen by 300%
$20 Appendix 4C - quarterly 29 Jan 2009 2:31PM $0.025 $0.088 risen by 252%
$20 West Nile Dosing Trials Completed. Avantogen now Acuvax 17 Dec 2008 10:47AM $0.050 $0.088 risen by 76%
$20 Draw Down Facility with Fortrend Securities 3 Dec 2008 11:50AM $0.030 $0.088 risen by 193.33%
$20 Appendix 4C - First Quarter Report 31 Oct 2008 12:31PM $0.040 $0.088 risen by 120%
$20 Hawaii Biotech Clinical Support from Walter Reed Institute 1 Sep 2008 10:25AM n/a $0.088 n/a
$20 Preliminary Final Report 29 Aug 2008 2:29PM $0.045 $0.088 risen by 95.56%
$20 Avantogen Receives Commitment of $1M in a Private Placement 20 Aug 2008 8:41AM $0.080 $0.088 risen by 10%
$20 Commitments Test Entity - Fourth Quarter Report 30 Jul 2008 10:12AM n/a $0.088 n/a

501 - 525 of 601 results

Page 21 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.